Maxigen BiotechTPE:1783 -1.55%87 ROA % is 18.61% as of Dec. 2025, which is 170% above its 10-year median of 6.90. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 858 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 94.52% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Maxigen Biotech's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$335.0 Mil.
Maxigen Biotech's average Total Assets over the quarter that ended in Dec. 2025 was NT$1,800.4 Mil. Therefore, Maxigen Biotech's annualized ROA % for the quarter that ended in Dec. 2025 was 18.61%.
The historical rank and industry rank for Maxigen Biotech's ROA % or its related term are showing as below:
TPE:1783'
s ROA % Range Over the Past 10 Years
Min: -1.08 Med: 6.9 Max: 15.48
Current: 15.48
During the past 13 years, Maxigen Biotech's highest ROA % was 15.48%. The lowest was -1.08%. And the median was 6.90%.
TPE:1783's ROA % is ranked better than 94.52% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs TPE:1783: 15.48
Maxigen Biotech (TPE:1783) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Maxigen Biotech ROA % Related Terms
Maxigen Biotech ROA % Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's ROA % distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Maxigen Biotech (TPE:1783) has a ROA % of 18.61% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Maxigen Biotech and its competitors. This is 170% above median its historical median of 6.90. According to the industry distribution chart, Maxigen Biotech ranks #47 out of 858 companies in the Medical Devices & Instruments industry, placing it in the top 5.5%.
Is Maxigen Biotech's ROA % too high?
Maxigen Biotech's current ROA % of 18.61% is 170% above median its 10-year median of 6.90. The Medical Devices & Instruments industry median ROA % is 0.55. Maxigen Biotech's value of 18.61% is 3314.7% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #47 out of 858 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #47 out of 858 companies for ROA %. This places Maxigen Biotech in the top 6% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Maxigen Biotech's value of 18.61% is 3314.7% above this benchmark. While the company's 10-year median is 6.90 vs. the industry median of 0.55, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current ROA % of 18.61% is 3314.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current ROA % is 18.61%, which is 170% above median its own 10-year median of 6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current ROA % is 18.61%, which is 170% above median its 10-year median of 6.90 and 3314.7% above the Medical Devices & Instruments industry median of 0.55. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current ROA % is 18.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
ROA %: 18.61% (170% above median its 10-year median of 6.90)
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
Industry Position: 3314.7% above the Medical Devices & Instruments median (#47 of 858)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
